The Institute for Experimental Immunology was founded in 2005 to combine the scientific activities of researching new antigens and developing innovative methods. Here, highly qualified scientists are working together on various projects. Without the Institute for Experimental Immunology, the majority of new developments from EUROIMMUN AG would have been unimaginable.
The most outstanding achievements of the institute include the following:
In 2009 a state-of-the-art mass spectrometer was put into operation at the Dassow subsidiary. With the additional expertise gained through this acquisition, new target antigens could be identified within a very short time, such as CUZD1 and GP-2 in Crohn's disease or DNA-bound lactoferrin in ulcerative colitis.